CD274 and metastatic melanoma: A Phase Ib study (NCT01656642) by Sullivan et al. investigated the combination of atezolizumab (anti-PD-L1) with either vemurafenib alone or vemurafenib plus cobimetinib in patients with BRAFV600-mutated metastatic melanoma[147].